Endo fights FTC’s “back-door” challenge

The Federal Trade Commission is using the Impax case about an alleged 2010 no-authorised-generic agreement to attack a patent settlement made just last August, Endo Pharmaceuticals said in a successful bid last week to intervene in the agency’s administrative proceeding.

Unlock unlimited access to all Global Competition Review content